Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer

Name: Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer
Published: 2021
License: Public Domain

University of Washington · 2021

ClinicalTrials.gov · Datasets · License: Public Domain · 2021

Open Source ↗

anatomic stage iii breast cancer ajcc v8, anatomic stage iv breast cancer ajcc v8, brca-associated malignant neoplasm, brca hereditary ovarian carcinoma, metastatic brca hereditary breast carcinoma, metastatic breast carcinoma, metastatic fallopian tube carcinoma, metastatic malignant solid neoplasm, metastatic ovarian carcinoma, metastatic pancreatic carcinoma, metastatic primary peritoneal carcinoma, prognostic stage iii breast cancer ajcc v8

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 833591
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.